Specifically, NPM1-, IDH1/2-, TET2-, and relapsed or refractory RUNX1-mutated AML patients present a high sensitivity to venetoclax combination therapy [78,79,80,81,82,83], while patients carrying FLT3, TP53, RAS, or PTPN11 mutations show a reduced sensitivity to venetoclax-based therapies. This evidence concerns the gene FLT3 and acute myeloid leukemia.